title: Assessment of the hemostatic effectiveness of human platelets treated with aminomethyltrimethyl psoralen and UV A light using a rabbit ear bleeding time technique.
abstract: The photochemical aminomethyltrimethyl psoralen (AMT), in conjunction with UV A light (UVA), has been shown to inactivate human immunodeficiency virus-1 and model viruses in platelet suspensions under conditions that have only a minimal effect on in vitro platelet properties. A rabbit ear bleeding time technique was used to assess the hemostatic effectiveness of human platelet suspensions treated with AMT/UVA. New Zealand White rabbits were made thrombocytopenic by a combination of irradiation and heterologous antirabbit platelet antiserum. Reticuloendothelial function in these rabbits was suppressed by the intravenous administration of ethyl palmitate. The hemostatic function of 1- and 5-day-old human platelet suspensions (14.5% plasma) that had been treated on day 1 with 40 micrograms/mL AMT and 24 kJ/m2 UVA (1 x UVA) was evaluated by measuring microvascular bleeding times after a standard incision. Comparable bleeding times were observed after infusion with both control and AMT/UVA-treated platelets stored for either 1 or 5 days. With the transfusion of AMT/1 x UVA-treated platelets stored for 5 days, the mean (+/- SD) bleeding time was 156.3 +/- 39.2 seconds (n = 10). With untreated platelets (no AMT/no UVA), stored for 5 days, the mean bleeding time was 189.2 +/- 36.4 seconds (n = 10). Neither AMT nor 1 x UVA treatment alone influenced the observed bleeding times. In contrast, the hemostatic effectiveness of human platelet suspensions was diminished if they were exposed to three times the standard UVA dose (72 kJ/m2) on day 1 and stored for 4 more days, regardless of whether AMT was present, with the mean bleeding time increasing to 442.2 +/- 122.6 seconds (n = 15, AMT present) or 396.0 +/- 45.9 seconds (n = 10, AMT absent). These results are consistent with data obtained from in vitro studies and indicate that virucidal AMT/1 x UVA treatment does not influence platelet hemostatic function. However, the final conditions to achieve these results must be carefully controlled.
authors.affiliation: Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, MD 20855.
authors.forename: S J
authors.initials: SJ
authors.lastname: Wagner
authors.forename: L
authors.initials: L
authors.lastname: Bardossy
authors.forename: G
authors.initials: G
authors.lastname: Moroff
authors.forename: R Y
authors.initials: RY
authors.lastname: Dodd
authors.forename: M A
authors.initials: MA
authors.lastname: Blajchman
mesh_terms: D000818:Animals; D001760:Bleeding Time; D001792:Blood Platelets / Q000187:drug effects*; D004423:Ear / Q000098:blood supply; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D011701:PUVA Therapy; D011817:Rabbits; D013535:Suspensions; D014307:Trioxsalen / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D013535:Suspensions; C018822:aminomethyltrioxsalen; D014307:Trioxsalen